[{"address1": "17 Drydock Avenue", "address2": "Suite 17-401", "city": "Boston", "state": "MA", "zip": "02210", "country": "United States", "phone": "617-461-4023", "website": "https://www.aktisoncology.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Aktis Oncology, Inc. operates as a clinical-stage oncology company that engages in the development of targeted radiopharmaceutical therapies for cancer treatment. The company offers a miniprotein radioconjugate platform to discover and develop radiopharmaceutical therapies that deliver the tumor-killing properties of radioisotopes. It offers Nectin-4, a miniprotein radioconjugate for the treatment of locally advanced or metastatic urothelial cancer. Its products include AKY-1189 to deliver a radioisotope to Nectin-4 expressing tumors for the treatment of metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and AKY-2519 to deliver radioisotope to B7-H3 CD276 expressing tumors targeting prostate, lung and other solid tumors. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is based in Boston, Massachusetts.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Todd  Foley M.B.A.", "age": 53, "title": "Co-Founder & Chairman", "yearBorn": 1972, "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Matthew  Roden Ph.D.", "title": "President, CEO & Director", "fiscalYear": 2025, "totalPay": 914680, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Paul L. Feldman Ph.D.", "age": 63, "title": "Chief Scientific Officer", "yearBorn": 1962, "fiscalYear": 2025, "totalPay": 642415, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Akos  Czibere M.D., Ph.D.", "age": 47, "title": "Chief Medical Officer", "yearBorn": 1978, "fiscalYear": 2025, "totalPay": 676930, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Patrick A. Baeuerle Ph.D.", "age": 67, "title": "Co-Founder & Member of Scientific Advisory Board", "yearBorn": 1958, "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kyle D. Kuvalanka", "age": 57, "title": "Chief Financial Officer", "yearBorn": 1968, "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Shulamit  Ron-Bigger Ph.D.", "age": 44, "title": "Chief Operating Officer", "yearBorn": 1981, "fiscalYear": 2025, "totalPay": 536714, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Tyler  Benedum Ph.D.", "title": "Chief Technical Officer", "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Carlos  Rodriguez", "title": "Executive Director of Corporate Development", "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Dasa  Lipovsek Ph.D.", "title": "VP & Head of Lead Discovery", "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1767139200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 19.64, "open": 19.91, "dayLow": 19.25, "dayHigh": 20.35, "regularMarketPreviousClose": 19.64, "regularMarketOpen": 19.91, "regularMarketDayLow": 19.25, "regularMarketDayHigh": 20.35, "payoutRatio": 0.0, "volume": 162497, "regularMarketVolume": 162497, "averageVolume": 553535, "averageVolume10days": 294100, "averageDailyVolume10Day": 294100, "bid": 20.11, "ask": 20.37, "bidSize": 1, "askSize": 1, "marketCap": 1063576192, "fiftyTwoWeekLow": 18.52, "fiftyTwoWeekHigh": 29.16, "allTimeHigh": 29.16, "allTimeLow": 18.52, "priceToSalesTrailing12Months": 191.29068, "fiftyDayAverage": 20.915714, "twoHundredDayAverage": 20.915714, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 64756148, "profitMargins": 0.0, "floatShares": 366822, "sharesOutstanding": 50649450, "sharesShort": 46658, "dateShortInterest": 1768435200, "sharesPercentSharesOut": 0.00090000004, "heldPercentInsiders": 0.12945, "heldPercentInstitutions": 0.41291, "shortRatio": 0.05, "impliedSharesOutstanding": 52522279, "bookValue": -162.432, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -60649000, "trailingEps": -1.15, "enterpriseToRevenue": 11.647, "enterpriseToEbitda": -0.914, "52WeekChange": -0.123214304, "SandP52WeekChange": 0.16255379, "quoteType": "EQUITY", "currentPrice": 20.25, "recommendationKey": "none", "totalCash": 297168000, "totalCashPerShare": 364.592, "ebitda": -70869000, "totalDebt": 12010000, "quickRatio": 9.183, "currentRatio": 9.268, "totalRevenue": 5560000, "debtToEquity": 4.89, "revenuePerShare": 7.008, "returnOnAssets": -0.14799, "returnOnEquity": -0.26504, "grossProfits": -58004000, "freeCashflow": -36264000, "operatingCashflow": -61685000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -16.75777, "financialCurrency": "USD", "symbol": "AKTS", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "longName": "Aktis Oncology, Inc.", "shortName": "Aktis Oncology, Inc.", "marketState": "CLOSED", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1767969000000, "regularMarketChangePercent": 3.1059096, "regularMarketPrice": 20.25, "postMarketChangePercent": 1.9753067, "postMarketPrice": 20.65, "postMarketChange": 0.39999962, "regularMarketChange": 0.6100006, "regularMarketDayRange": "19.25 - 20.35", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 553535, "fiftyTwoWeekLowChange": 1.7299995, "fiftyTwoWeekLowChangePercent": 0.0934125, "fiftyTwoWeekRange": "18.52 - 29.16", "fiftyTwoWeekHighChange": -8.91, "fiftyTwoWeekHighChangePercent": -0.30555555, "fiftyTwoWeekChangePercent": -12.32143, "epsTrailingTwelveMonths": -1.15, "fiftyDayAverageChange": -0.66571426, "fiftyDayAverageChangePercent": -0.031828426, "twoHundredDayAverageChange": -0.66571426, "twoHundredDayAverageChangePercent": -0.031828426, "priceToBook": -0.12466755, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2026-01-09", "cryptoTradeable": false, "corporateActions": [], "postMarketTime": 1769820946, "regularMarketTime": 1769806802, "exchange": "NMS", "messageBoardId": "finmb_708181619", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "displayName": "Aktis Oncology", "trailingPegRatio": null, "__fetch_time": "2026-01-31"}]